che-chandler.de
Leading Pharmaceutical Innovation
Trends and Drivers for Growth in the Pharmaceutical Industry
HC runder Rücken kaschiert
Print on Demand | Lieferzeit: Print on Demand - Lieferbar innerhalb von 3-5 Werktagen I
Alle Preise inkl. MwSt. | Versandkostenfrei
Nicht verfügbar
Zum Merkzettel
Gewicht:
477 g
Format:
241x160x17 mm
Beschreibung:
Prof. Dr. Oliver Gassmann ist Professor für Technologiemanagement und Direktor des Instituts für Technologiemanagement an der Universität St. Gallen.
Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D. Our findings are illustrated not only in cases of Swiss pharmaceutical industry, but also by industry cases from the US and Asia.
Innovation: Key to Success in the Pharmaceutical Industry.- The Industry Challenge: Do You Really Want to Be in This Business?.- The Science and Technology Challenge: How to Find New Drugs.- The Pipeline Management Challenge: How to Organize Innovation.- The Internationalization Challenge: Where to Get Access to Innovation.- Management Answers to Pharmaceutical R&D Challenges.- Future Directions and Trends.
Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. Our findings are illustrated by cases from Europe, the US, and Asia.